PharmaVoice

JANUARY 2, 2025

A handful of innovative startups are scrambling to gain a foothold as technology improves at a rapid clip.

126

126

MedCity News

JANUARY 2, 2025

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions. The post FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions appeared first on MedCity News.

FDA 115

FDA Medicine Biopharma Pharma 115

PharmaTech

DECEMBER 31, 2024

The PharmTech Group editors present our most popular technical articles from 2024.

98

98

PharmaTimes

JANUARY 2, 2025

New chemotherapy-free treatment shows promise for EGFR-mutated NSCLC

94

94

Advertiser: ZoomInfo

Savvy B2B marketers know that a great account-based marketing (ABM) strategy leads to higher ROI and sustainable growth. In this guide, we’ll cover: What makes for a successful ABM strategy? What are the key elements and capabilities of ABM that can make a real difference? How is AI changing workflows and driving functionality? This Martech Intelligence Report on Enterprise Account-Based Marketing examines the state of ABM in 2024 and what to consider when implementing ABM software.

Marketing

pharmaphorum

JANUARY 3, 2025

CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satri-cel has shown efficacy in gastric cancer, setting up a filing in China.

90

90

European Pharmaceutical Review

JANUARY 2, 2025

The National Institute for Health and Care Excellence (NICE) has recommended the first drug for NHS use to prevent cisplatin-induced hearing loss ( ototoxicity ) in children and young people between the ages of one month and 17 years old.Pedmarqsi (anhydrous sodium thiosulfate) is indicated for these children who have localised, non-metastatic, solid tumours.

Side effects 59

Side effects Medicine Government Pharmaceutical 59

Pharma Marketing Network

DECEMBER 31, 2024

Table of Contents Sr# Headings 1 Introduction: The Pharma Marketing Challenge 2 Building a Winning Pharma Marketing Strategy 3 The Role of Branded Drug Campaigns 4 Innovating for Future Success Introduction: The Pharma Marketing Challenge Marketing pharmaceuticals is no small feat. In an industry where lives are at stake, creating compelling, compliant, and effective campaigns can feel like walking a tightrope.

Marketing 52

Marketing Pharmaceutical Pharma Education 52

PharmaTimes

JANUARY 2, 2025

MHRA urges caution over illegal medicines from beauty salons and social media

Medicine 87

Medicine Prescription Media 87

pharmaphorum

JANUARY 3, 2025

Capricor completes its US filing for deramiocel, vying to become the first FDA-approved therapy for cardiomyopathy in Duchenne muscular dystrophy.

FDA 90

FDA 90

PharmaTech

JANUARY 2, 2025

The guidance provides recommendations for those interested in participating in FDAs Advanced Manufacturing Technologies Designation Program.

Manufacturing 69

Manufacturing FDA 69

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

MedCity News

DECEMBER 30, 2024

One Phase 3 test of Auvelity met its main goal in Alzheimers agitation while the drugs other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimers agitation drug. The post Axsome Aims for FDA Filing in Alzheimers Agitation Despite Mixed Bag of Phase 3 Data appeared first on MedCity News.

FDA 94

FDA Pharmaceutical products Pharmaceutical Biopharma 94

European Pharmaceutical Review

JANUARY 2, 2025

The RNA therapeutics industry stands poised for a transformative 2025, driven by breakthroughs in technology, expanding clinical applications, and a rapidly growing pipeline of innovative therapies. Following the unprecedented speed and success of mRNA-based COVID-19 vaccine development, the field has experienced a surge in investment and research to unlock the powerful potential of RNA for other therapeutic applications.

Manufacturing 59

Manufacturing Food and Drug Administration FDA Pharmaceutical 59

PharmaTimes

JANUARY 3, 2025

FDA gives green light to innovative device for liver conditions

FDA 85

FDA 85

pharmaphorum

JANUARY 2, 2025

Early cancer diagnoses have risen to record levels in England, says NHS, but long waiting times for treatment threaten to undermine the gains.

90

90

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

Pharmaceutical Technology

JANUARY 3, 2025

The Indian Institute of Technology (IIT) Guwahati and the Bose Institute Kolkata research team have developed an advanced injectable hydrogel

64

64

MedCity News

DECEMBER 31, 2024

Amid the chaos and confusion of healthcare IT in our age of AI, a triage concept may be the best guide for organizations fighting to stray strong and capable in 2025 and beyond. The post Healthcare IT in 2025: Triage for the Age of AI appeared first on MedCity News.

Healthcare 95

Healthcare Healthcare 95

PharmaVoice

JANUARY 3, 2025

Pharma companies stepped up to support The Carter Center and provide access to life-saving treatments.

Pharma 64

Pharma 64

PharmaTimes

JANUARY 3, 2025

Government announces independent commission on social care

Government 82

Government 82

Advertisement

pharmaphorum

DECEMBER 31, 2024

Sangamo is 'surprised and disappointed' by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results

87

87

PharmaTech

JANUARY 2, 2025

The company is recalling one lot of PROGRAF 0.5mg (tacrolimus) and one lot of ASTAGRAF XL 0.5mg (tacrolimus extended-release) capsules because some bottles may contain empty capsules.

Pharma 64

Pharma 64

MedCity News

DECEMBER 31, 2024

Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now looking for a new partner for the program. The post Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing appeared first on MedCity News.

FDA 101

FDA Biopharma Pharma 101

Pharmaceutical Technology

JANUARY 2, 2025

Effective management of atopic dermatitis (AD) has been one of the top priorities for physicians over the years, as quality of life in these patients is compromised due to the disruptive symptoms that they experience, which include itchiness and skin inflammation.

Management 64

Management Physicians Patients 64

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

PharmaTimes

JANUARY 6, 2025

IMDYLLTRA offers new hope for patients with extensive-stage small cell lung cancer

Patients 62

Patients 62

pharmaphorum

DECEMBER 30, 2024

BMS beats MSD to the US subcutaneous PD-1 inhibitor market after Opdivo Qvantiq is cleared across nearly all the indications of the IV form

Marketing 79

Marketing 79

PharmaTech

DECEMBER 30, 2024

The PharmTech Group editors present our most popular interviews from 2024.

64

64

MedCity News

JANUARY 2, 2025

About 79% of digital health leaders said their companies are pursuing new investment capital in the next year, according to a recent survey from Summit Health Advisors. The post Top Priorities and Challenges for Digital Health Leaders in 2025: 5 Key Insights appeared first on MedCity News.

85

85

Advertiser: ZoomInfo

Over the last two years, there’s been a 76 percent increase in AI adoption across sales organizations. The reason for its rise? AI increases teams’ productivity by predicting and automating actions that require manual effort. In other words, the research that takes reps hours, AI can do in seconds. For sales teams, AI opens up a world of new possibilities, including automating outreach, identifying best-fit buyers, and keeping CRMs flush with fresh data.

Sales

Pharmaceutical Technology

JANUARY 2, 2025

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

Medical 64

Medical Marketing 64

PharmaTimes

JANUARY 6, 2025

EpiSwitch PSE shows promise in reducing unnecessary procedures

62

62

pharmaphorum

JANUARY 2, 2025

The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price

77

77

European Pharmaceutical Review

JANUARY 3, 2025

Researchers have developed a high performance liquid chromatography (HPLC) method that enables accurate determination and precise impurity analysis of the adrenergic -receptor blocker Carvedilol. Carvedilol is commonly used drug to treat cardiovascular diseases , Yuan et al. explained. While there are a variety of methods that can detect and quantify carvedilol, these methods often have limitations in terms of sensitivity, selectivity, or the ability to simultaneously quantify carvedilol and its

Pharmaceutical manufacturing 52

Pharmaceutical manufacturing Manufacturing Pharmaceutical Safety 52

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales